Hypertension, Obesity, and COVID-19: a Collision of Pandemics

Perez, Annalisa; Naljayan, Mihran; Shuja, Imran; Florea, Andre; Reisin, Efrain

doi:10.1007/s11906-021-01153-6

Cited by 19 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, populations in rural areas, such as rural Kentucky, tend to have high rates of obesity, diabetes, and hypertension compared to other regions of the U.S. [ 25 , 26 ]. Patients with hypertension or diabetes are more likely to experience severe cases of COVID-19 [ 27 ]. At the same time, those with body mass index measures (BMI) greater than 25 were nearly four times as likely to die and eight times as likely to need advanced respiratory support as a result of their COVID-19 infection [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave

et al. 2022

View full text Add to dashboard Cite

Background The novel coronavirus pandemic (COVID-19) has had severe impacts on morbidity and mortality globally. Methods This study was set in rural central Kentucky and included participants recruited from public spaces. Fifteen qualitative interviews about personal experiences during the COVID-19 pandemic were conducted by phone from July 3 to July 24, 2020. Interviews were recorded, transcribed, and coded using a grounded theory approach. Results Participants who perceived COVID-19 to be a severe risk tended to have personal health concerns and therefore reported taking protective measures for themselves. A slightly smaller proportion of participants reported taking measures to protect others (particularly family). A minority of participants had an ambivalent attitude towards the risk and only took measures if required. COVID-19 vaccine acceptability was low with most participants expressing concerns regarding their need for a vaccine, safety of this vaccine, the value of personal rights, or future vaccine supply. Conclusions Most participants perceived some risk of COVID-19 and took steps to prevent infections in themselves and others. Mandates for mask use in certain locations were additionally useful for those who had an ambivalent attitude towards the risk of illness. There was surprisingly little connection between perceiving COVID-19 risk and a desire for the COVID-19 vaccine. In this setting, vaccine acceptability was low, with vaccine concerns outweighing perceived potential benefits. In conclusion, because the risk was often constructed in terms of worries for themselves and others, the framing of health education materials for protective behaviors in these terms may be effective. Furthermore, future COVID-19 vaccine education should address vaccine knowledge and concerns, such as the need for a vaccine and its safety, and emphasize how a vaccination would reduce their chances of severe disease if they were to get sick.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave

et al. 2022

View full text Add to dashboard Cite

show abstract

“…LDH levels and glycaemia mediate the outcome of COVID-19 severity [21]. However, the correlations of these markers with hypertension and lack of hypertension in COVID-19 patients and with mortality are still not fully understood [14]. γ-glutamyl transpeptidase (GGT) and albumin (ALB), ALT, AST are serum biochemical parameters, which can reflect the liver physiological function.…”

Section: Introductionmentioning

confidence: 99%

Abnormal myocardial enzymes in the prediction of mortality and hypertension in COVID-19 patients: a retrospective study

Sha

Liu

Sun

et al. 2022

Aging

View full text Add to dashboard Cite

This study aims to determine the differences in myocardial enzymes in COVID-19 patients with and without hypertension. A total of 130 patients with COVID-19 in Yunmeng County People's Hospital were analyzed. The clinical manifestations and laboratory indicators were collected and analyzed. We found that COVID-19 patients with hypertension had higher mortality rate, greater age, and higher rates of basic disease such as diabetes than patients without hypertension. The γ-glutamyl transpeptidase (GGT), blood urea nitrogen (BUN), albumin/globulin (A/G), Ca, Mg, lactate dehydrogenase (LDH), and ɑ-hydroxybutyric-dehydrogenase (ɑ-HBD) levels in COVID-19 patients with hypertension were higher than in COVID-19 patients without hypertension. We found that the predictive effect of the creatine kinase isoenzyme (CK-MB), LDH-L, and ɑ-HBD levels in the COVID-19 patients without hypertension were higher than in COVID-19 patients with hypertension. We used the ROC curve model to predict whether patients would have hypertension, and we found that CK-MB, LDH-L and HBD parameters could distinguish the COVID-19 patients with hypertension and non-hypertension, and could predict the mortality of COVID-19 patients.

show abstract

“…The concentrations of pyroglutamine in the blood serum were increased in patients who took antihypertensives such as beta-blockers [ 26 ]. Hypertension has emerged as significant risk factors for COVID-19 [ 27 ]. Antihypertensive drugs have been implicated in COVID-19 susceptibility and severity [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Mendelian Randomization Study on Causal Association of Pyroglutamine with COVID-19

Zhou

Zhu

et al. 2022

J Epidemiol Glob Health

View full text Add to dashboard Cite

Background Glutamine family amino acids such as glutamate, pyroglutamate, and glutamine have been shown to play important roles in COVID-19. However, it is still unclear about the role of pyroglutamate in COVID-19. Thus, we use a two-sample Mendelian randomization (MR) study to identify the genetic causal link between blood pyroglutamine levels and COVID-19 risk. Methods Pyroglutamine genetic instrumental variables (IVs) were chosen from the largest pyroglutamine-associated genome-wide association studies (GWAS). The largest COVID-19 GWAS dataset was employed to evaluate the causal link between blood pyroglutamine levels and COVID-19 risk using two-sample MR analysis. Results We found no significant pleiotropy or heterogeneity of pyroglutamine-associated genetic IVs in COVID-19 GWAS. Interestingly, we found that as pyroglutamine genetically increased, the risk of COVID-19 decreased using inverse variance weighted (IVW) (Beta = − 0.644, p = 0.003; OR = 0.525, 95% CI [0.346–0.798]) and weighted median (Beta = − 0.609, p = 0.013; OR = 0.544, 95% CI [0.337–0.878]). Conclusion Our analysis suggests a causal link between genetically increased pyroglutamine and reduced risk of COVID-19. Thus, pyroglutamine may be a protective factor for patients with COVID-19.

show abstract

Hypertension, Obesity, and COVID-19: a Collision of Pandemics

Cited by 19 publications

References 32 publications

Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave

Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave

Abnormal myocardial enzymes in the prediction of mortality and hypertension in COVID-19 patients: a retrospective study

Mendelian Randomization Study on Causal Association of Pyroglutamine with COVID-19

Contact Info

Product

Resources

About